GSTDTAP  > 地球科学
DOI10.1038/nature20136
Targeting cardiac fibrosis with engineered T cells
Aghajanian, Haig1,2,3; Kimura, Toru4; Rurik, Joel G.1,2,3; Hancock, Aidan S.1,2,3; Leibowitz, Michael S.5,6; Li, Li1,2,3; Scholler, John7; Monslow, James8; Lo, Albert8; Han, Wei9; Wang, Tao2; Bedi, Kenneth2,4; Morley, Michael P.2,4; Saldana, Ricardo A. Linares1,2,3; Bolar, Nikhita A.1,2,3; McDaid, Kendra2; Assenmacher, Charles-Antoine10; Smith, Cheryl L.1,2,3; Wirth, Dagmar11; June, Carl H.7; Margulies, Kenneth B.2,4; Jain, Rajan1,2,3,4; Pure, Ellen8; Albelda, Steven M.4; Epstein, Jonathan A.1,2,3,4
2019-09-19
发表期刊NATURE
ISSN0028-0836
EISSN1476-4687
出版年2019
卷号573期号:7774页码:430-+
文章类型Article
语种英语
国家USA; Germany
英文摘要

Fibrosis is observed in nearly every form of myocardial disease(1). Upon injury, cardiac fibroblasts in the heart begin to remodel the myocardium by depositing excess extracellular matrix, resulting in increased stiffness and reduced compliance of the tissue. Excessive cardiac fibrosis is an important factor in the progression of various forms of cardiac disease and heart failure(2). However, clinical interventions and therapies that target fibrosis remain limited(3). Here we demonstrate the efficacy of redirected T cell immunotherapy to specifically target pathological cardiac fibrosis in mice. We find that cardiac fibroblasts that express a xenogeneic antigen can be effectively targeted and ablated by adoptive transfer of antigen-specific CD8(+) T cells. Through expression analysis of the gene signatures of cardiac fibroblasts obtained from healthy and diseased human hearts, we identify an endogenous target of cardiac fibroblasts-fibroblast activation protein. Adoptive transfer of T cells that express a chimeric antigen receptor against fibroblast activation protein results in a significant reduction in cardiac fibrosis and restoration of function after injury in mice. These results provide proof-of-principle for the development of immunotherapeutic drugs for the treatment of cardiac disease.


领域地球科学 ; 气候变化 ; 资源环境
收录类别SCI-E
WOS记录号WOS:000486647800053
WOS关键词FIBROBLAST ACTIVATION PROTEIN ; MOLECULAR-CLONING ; EXPRESSION ; STROMA ; ALPHA
WOS类目Multidisciplinary Sciences
WOS研究方向Science & Technology - Other Topics
URL查看原文
引用统计
文献类型期刊论文
条目标识符http://119.78.100.173/C666/handle/2XK7JSWQ/202683
专题地球科学
资源环境科学
气候变化
作者单位1.Univ Penn, Perelman Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA;
2.Univ Penn, Perelman Sch Med, Penn Cardiovasc Inst, Philadelphia, PA 19104 USA;
3.Univ Penn, Perelman Sch Med, Inst Regenerat Med, Philadelphia, PA 19104 USA;
4.Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA;
5.Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA;
6.Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA;
7.Univ Penn, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA;
8.Univ Penn, Sch Vet Med, Dept Biomed Sci, Philadelphia, PA 19104 USA;
9.Hosp Univ Penn, Echocardiog Lab, 3400 Spruce St, Philadelphia, PA 19104 USA;
10.Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA;
11.Helmholtz Ctr Infect Res, Model Syst Infect & Immun, Braunschweig, Germany
推荐引用方式
GB/T 7714
Aghajanian, Haig,Kimura, Toru,Rurik, Joel G.,et al. Targeting cardiac fibrosis with engineered T cells[J]. NATURE,2019,573(7774):430-+.
APA Aghajanian, Haig.,Kimura, Toru.,Rurik, Joel G..,Hancock, Aidan S..,Leibowitz, Michael S..,...&Epstein, Jonathan A..(2019).Targeting cardiac fibrosis with engineered T cells.NATURE,573(7774),430-+.
MLA Aghajanian, Haig,et al."Targeting cardiac fibrosis with engineered T cells".NATURE 573.7774(2019):430-+.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Aghajanian, Haig]的文章
[Kimura, Toru]的文章
[Rurik, Joel G.]的文章
百度学术
百度学术中相似的文章
[Aghajanian, Haig]的文章
[Kimura, Toru]的文章
[Rurik, Joel G.]的文章
必应学术
必应学术中相似的文章
[Aghajanian, Haig]的文章
[Kimura, Toru]的文章
[Rurik, Joel G.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。